ATE517879T1 - 4-hydroxy-2-oxo-2,3-dihydro-1,3-benzothiazol-7- ylverbindungen zum modulieren der b2- adrenorezeptoraktivität - Google Patents
4-hydroxy-2-oxo-2,3-dihydro-1,3-benzothiazol-7- ylverbindungen zum modulieren der b2- adrenorezeptoraktivitätInfo
- Publication number
- ATE517879T1 ATE517879T1 AT07848598T AT07848598T ATE517879T1 AT E517879 T1 ATE517879 T1 AT E517879T1 AT 07848598 T AT07848598 T AT 07848598T AT 07848598 T AT07848598 T AT 07848598T AT E517879 T1 ATE517879 T1 AT E517879T1
- Authority
- AT
- Austria
- Prior art keywords
- benzothiazole
- dihydro
- oxo
- modulating
- hydroxy
- Prior art date
Links
- -1 4-HYDROXY-2-OXO-2,3-DIHYDRO-1,3-BENZOTHIAZOLE-7-YL COMPOUNDS Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/08—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D277/12—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/14—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/14—Thiadiazoles; Hydrogenated thiadiazoles condensed with carbocyclic rings or ring systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US87092206P | 2006-12-20 | 2006-12-20 | |
| US91004507P | 2007-04-04 | 2007-04-04 | |
| US95198007P | 2007-07-26 | 2007-07-26 | |
| PCT/GB2007/004861 WO2008075026A1 (en) | 2006-12-20 | 2007-12-19 | 4-hydr0xy-2-0x0-2, 3 -dihydro- 1, 3-benzothiazol- 7yl compounds for modulation of b2-adrenoreceptor activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE517879T1 true ATE517879T1 (de) | 2011-08-15 |
Family
ID=39167020
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT07848598T ATE517879T1 (de) | 2006-12-20 | 2007-12-19 | 4-hydroxy-2-oxo-2,3-dihydro-1,3-benzothiazol-7- ylverbindungen zum modulieren der b2- adrenorezeptoraktivität |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US7700782B2 (de) |
| EP (1) | EP2121642B1 (de) |
| JP (1) | JP2010513440A (de) |
| KR (1) | KR20090091342A (de) |
| AR (1) | AR064635A1 (de) |
| AT (1) | ATE517879T1 (de) |
| AU (1) | AU2007336075B2 (de) |
| BR (1) | BRPI0722096A2 (de) |
| CA (1) | CA2672811A1 (de) |
| CL (1) | CL2007003765A1 (de) |
| CO (1) | CO6190554A2 (de) |
| EC (1) | ECSP099426A (de) |
| IL (1) | IL199014A0 (de) |
| MX (1) | MX2009006009A (de) |
| NO (1) | NO20092691L (de) |
| PE (1) | PE20081544A1 (de) |
| SA (1) | SA07280728B1 (de) |
| TW (1) | TW200833670A (de) |
| UY (1) | UY30808A1 (de) |
| WO (1) | WO2008075026A1 (de) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200738658A (en) * | 2005-08-09 | 2007-10-16 | Astrazeneca Ab | Novel compounds |
| TW200738659A (en) * | 2005-08-29 | 2007-10-16 | Astrazeneca Ab | Novel compounds |
| TW200745067A (en) * | 2006-03-14 | 2007-12-16 | Astrazeneca Ab | Novel compounds |
| TW200825084A (en) | 2006-11-14 | 2008-06-16 | Astrazeneca Ab | New compounds 521 |
| TW200833670A (en) * | 2006-12-20 | 2008-08-16 | Astrazeneca Ab | Novel compounds 569 |
| GB0702458D0 (en) * | 2007-02-08 | 2007-03-21 | Astrazeneca Ab | Salts 668 |
| US8329729B2 (en) | 2008-05-13 | 2012-12-11 | Astrazeneca Ab | Quinuclidine derivatives as muscarinic M3 receptor antagonists |
| EP2315589A4 (de) * | 2008-05-13 | 2013-09-11 | Astrazeneca Ab | Pharmazeutisches produkt enthaltend einen muscarin-rezeptor-antagonisten und einen beta2-adrenorezeptor-agonisten |
| JP2011524896A (ja) | 2008-06-18 | 2011-09-08 | アストラゼネカ・アクチエボラーグ | 呼吸器障害の処置用のベータ２−アドレナリン受容体アゴニストとして作用するベンズオキサジノン誘導体 |
| WO2009154562A1 (en) * | 2008-06-20 | 2009-12-23 | Astrazeneca Ab | Pharmaceutical composition comprising a 4-hydroxy-2-oxo-2, 3- dihydro-1, 3-benzothiazol-7-yl compound for modulation of beta2-adrenoreceptor activity |
| GB0814728D0 (en) * | 2008-08-12 | 2008-09-17 | Argenta Discovery Ltd | New combination |
| TW201036957A (en) | 2009-02-20 | 2010-10-16 | Astrazeneca Ab | Novel salt 628 |
| GB0913342D0 (en) | 2009-07-31 | 2009-09-16 | Astrazeneca Ab | Compounds - 801 |
| WO2011061527A1 (en) | 2009-11-17 | 2011-05-26 | Astrazeneca Ab | Combinations comprising a glucocorticoid receptor modulator for the treatment of respiratory diseases |
| GB201016912D0 (en) | 2010-10-07 | 2010-11-24 | Astrazeneca Ab | Novel combination |
| JO3192B1 (ar) | 2011-09-06 | 2018-03-08 | Novartis Ag | مركب بنزوثيازولون |
| WO2015050984A1 (en) * | 2013-10-01 | 2015-04-09 | New York University | Amino, amido, and heterocyclic compounds as modulators of rage activity and uses thereof |
Family Cites Families (76)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2653977A (en) | 1953-09-29 | Chxnx | ||
| US3775477A (en) | 1971-03-10 | 1973-11-27 | Sterling Drug Inc | N,n'-bis(2-aryl-2-(hydroxy or oxo)-ethyl)-bridged-bis-carboxamides |
| US4460581A (en) | 1982-10-12 | 1984-07-17 | Boehringer Ingelheim Kg | (1-Hydroxy-2-amino-alkyl)-substituted benzoxazinones and benzoxazolinones |
| DE3571808D1 (en) | 1984-04-17 | 1989-08-31 | Glaxo Group Ltd | Ethanolamine compounds |
| US4554284A (en) | 1984-09-12 | 1985-11-19 | Smithkline Beckman Corporation | 7-(2-Aminoethyl)-1,3-benzthia- or oxa-zol-2(3H)-ones |
| US4554287A (en) | 1984-09-12 | 1985-11-19 | Smithkline Beckman Corporation | Antihypertensive 7-[2-(dialkylamino)ethyl]-4-hydroxy-1,3-benzimidazol-2-ones |
| GB8525483D0 (en) | 1985-10-16 | 1985-11-20 | Glaxo Group Ltd | Chemical compounds |
| GB8718938D0 (en) | 1987-08-11 | 1987-09-16 | Glaxo Group Ltd | Chemical compounds |
| JPH03133946A (ja) | 1989-10-10 | 1991-06-07 | Glaxo Group Ltd | フェンエタノールアミン化合物 |
| GB9211172D0 (en) | 1992-05-27 | 1992-07-08 | Fisons Plc | Compounds |
| US5648370A (en) | 1990-11-20 | 1997-07-15 | Astra Pharmaceuticals Limited | 7-(2-aminoethyl) benzothiazolones |
| IE914003A1 (en) * | 1990-11-20 | 1992-05-20 | Astra Pharma Prod | Biologically Active Amines |
| GB9210632D0 (en) | 1992-05-19 | 1992-07-01 | Fisons Plc | Compounds |
| TW356468B (en) * | 1995-09-15 | 1999-04-21 | Astra Pharma Prod | Benzothiazolone compounds useful as beta2-adrenoreceptor and dopamine DA2 receptor agonists process for preparing same and pharmaceutical compositions containing same |
| GB9526511D0 (en) | 1995-12-23 | 1996-02-28 | Astra Pharma Prod | Pharmaceutically active compounds |
| EP0914319B1 (de) | 1996-05-20 | 2001-11-21 | Teijin Limited | Cyclischer diarylalkyl diaminederivate als antogoniste von chemokinerezeptoren |
| SE9700706D0 (sv) | 1997-02-27 | 1997-02-27 | Astra Pharma Prod | Process for the preparation of benzothiazoline compounds |
| SE9701304D0 (sv) | 1997-04-09 | 1997-04-09 | Astra Pharma Prod | Compounds |
| US20020010197A1 (en) | 1998-01-13 | 2002-01-24 | John Dixon | Pharmaceutical compositions comprising a compound having dopamine (d2) receptor agonist activity and a compound (b) having beta2-adrenoreceptor agonist activity |
| US6362371B1 (en) | 1998-06-08 | 2002-03-26 | Advanced Medicine, Inc. | β2- adrenergic receptor agonists |
| GB9913083D0 (en) | 1999-06-04 | 1999-08-04 | Novartis Ag | Organic compounds |
| US6683115B2 (en) | 1999-06-02 | 2004-01-27 | Theravance, Inc. | β2-adrenergic receptor agonists |
| SE9902935D0 (sv) | 1999-08-18 | 1999-08-18 | Astra Pharma Prod | Pharmaceutical compositions |
| SE9902938D0 (sv) | 1999-08-18 | 1999-08-18 | Astra Pharma Prod | Pharmaceutical compositions |
| SE9902936D0 (sv) | 1999-08-18 | 1999-08-18 | Astra Pharma Prod | Pharmaceutical compositions |
| SE9902937D0 (sv) | 1999-08-18 | 1999-08-18 | Astra Pharma Prod | Pharmaceutical compositions |
| OA11558A (en) | 1999-12-08 | 2004-06-03 | Advanced Medicine Inc | Beta 2-adrenergic receptor agonists. |
| US6506901B2 (en) | 2000-07-17 | 2003-01-14 | Wyeth | Substituted 2-(S)-hydroxy-3-(piperidin-4-yl-methylamino)-propyl ethers and substituted 2-aryl-2-(R)-hydroxy-1-(piperidin-4-yl-methyl)-ethylamine β-3 adrenergic receptor agonists |
| ATE381537T1 (de) | 2001-03-22 | 2008-01-15 | Glaxo Group Ltd | Formanilid-derivative als beta2-adrenorezeptor- agonisten |
| ES2438985T3 (es) | 2001-09-14 | 2014-01-21 | Glaxo Group Limited | Formulación de inhalación que comprende derivados de fenetanolamina para el tratamiento de enfermedades respiratorias |
| US20030229058A1 (en) | 2001-11-13 | 2003-12-11 | Moran Edmund J. | Aryl aniline beta2 adrenergic receptor agonists |
| GB0217225D0 (en) | 2002-07-25 | 2002-09-04 | Glaxo Group Ltd | Medicinal compounds |
| AR040962A1 (es) | 2002-08-09 | 2005-04-27 | Novartis Ag | Compuestos derivados de tiazol 1,3-2-ona, composicion farmaceutica y proceso de preparacion del compuesto |
| GB0225540D0 (en) | 2002-11-01 | 2002-12-11 | Glaxo Group Ltd | Medicinal compounds |
| PE20040950A1 (es) | 2003-02-14 | 2005-01-01 | Theravance Inc | DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS |
| GB0303396D0 (en) | 2003-02-14 | 2003-03-19 | Glaxo Group Ltd | Medicinal compounds |
| JP4767842B2 (ja) | 2003-04-01 | 2011-09-07 | セラヴァンス， インコーポレーテッド | β２アドレナリン作用性レセプターアゴニスト活性およびムスカリン性レセプターアンタゴニスト活性を有するジアリールメチル化合物および関連化合物 |
| TW200526547A (en) | 2003-09-22 | 2005-08-16 | Theravance Inc | Amino-substituted ethylamino β2 adrenergic receptor agonists |
| GB0324654D0 (en) | 2003-10-22 | 2003-11-26 | Glaxo Group Ltd | Medicinal compounds |
| GB0324886D0 (en) | 2003-10-24 | 2003-11-26 | Glaxo Group Ltd | Medicinal compounds |
| JP2005187357A (ja) | 2003-12-25 | 2005-07-14 | Nippon Suisan Kaisha Ltd | 選択的なβ２受容体アゴニスト活性を有するベンゾチアゾロン誘導体の製造方法 |
| TW200531692A (en) | 2004-01-12 | 2005-10-01 | Theravance Inc | Aryl aniline derivatives as β2 adrenergic receptor agonists |
| GB0402797D0 (en) | 2004-02-09 | 2004-03-10 | Novartis Ag | Organic compounds |
| WO2005092861A1 (en) | 2004-03-11 | 2005-10-06 | Pfizer Limited | Quinolinone derivatives pharmaceutical compositions containing them and their use |
| EP1577306A1 (de) | 2004-03-17 | 2005-09-21 | Boehringer Ingelheim Pharma GmbH & Co.KG | Neue Benzoxazinonderivate als langwirksame Betamimetika zur Behandlung von Atemwegserkrankungen |
| WO2005092841A1 (en) | 2004-03-23 | 2005-10-06 | Pfizer Limited | Compounds having beta-agonist activity |
| WO2005110990A1 (de) | 2004-05-13 | 2005-11-24 | Boehringer Ingelheim International Gmbh | Hydroxy-substituierte benzkondensierte heterozyklen als betaagonisten zur behandlung von atemwegserkrankungen |
| EP1595873A1 (de) | 2004-05-13 | 2005-11-16 | Boehringer Ingelheim Pharma GmbH & Co.KG | Substituierte Cycloalkylderivate zur Behandlung von Atemswegerkrankungen |
| DE102004024453A1 (de) | 2004-05-14 | 2006-01-05 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue langwirksame Bronchodilatoren zur Behandlung von Atemwegserkrankungen |
| EP1751086A2 (de) | 2004-06-03 | 2007-02-14 | Theravance, Inc. | DIAMINVERBINDUNGEN ALS AGONISTEN DES ß2 ADRENERGEN REZEPTORS |
| JP2008507532A (ja) | 2004-07-21 | 2008-03-13 | セラヴァンス， インコーポレーテッド | ジアリールエーテルβ２アドレナリン作用性レセプターアゴニスト |
| JP2008510014A (ja) | 2004-08-16 | 2008-04-03 | セラヴァンス， インコーポレーテッド | β２アドレナリン作用性レセプターアゴニスト活性およびムスカリン性レセプターアンタゴニスト活性を有する化合物 |
| JP2008510015A (ja) | 2004-08-16 | 2008-04-03 | セラヴァンス， インコーポレーテッド | β２アドレナリン作用性レセプターアゴニスト活性およびムスカリン性レセプターアンタゴニスト活性を有する化合物 |
| EP1786762A2 (de) | 2004-09-10 | 2007-05-23 | Theravance, Inc. | Amidin-substituierte arylanilinverbindungen |
| GB0426164D0 (en) | 2004-11-29 | 2004-12-29 | Novartis Ag | Organic compounds |
| EA200701260A1 (ru) | 2005-01-11 | 2008-02-28 | Глаксо Груп Лимитед | Циннаматные соли бета-2 адренергического агониста |
| GB0511066D0 (en) | 2005-05-31 | 2005-07-06 | Novartis Ag | Organic compounds |
| NZ585580A (en) | 2005-07-18 | 2011-08-26 | Pfizer Ltd | Process for the preparation of sulfonamide derivatives |
| TW200738658A (en) | 2005-08-09 | 2007-10-16 | Astrazeneca Ab | Novel compounds |
| TW200740781A (en) * | 2005-08-29 | 2007-11-01 | Astrazeneca Ab | Novel compounds |
| TW200738659A (en) | 2005-08-29 | 2007-10-16 | Astrazeneca Ab | Novel compounds |
| TW200745084A (en) | 2006-03-08 | 2007-12-16 | Astrazeneca Ab | Novel compounds |
| US20090029958A1 (en) | 2006-03-08 | 2009-01-29 | Lilian Alcaraz | Phenethanolamine derivatives as beta2 adrenoreceptor agonists |
| TW200745067A (en) | 2006-03-14 | 2007-12-16 | Astrazeneca Ab | Novel compounds |
| WO2008041914A1 (en) | 2006-10-06 | 2008-04-10 | Astrazeneca Ab | 5-(2-AMINO-L-HYDROXYETHYL)-8-HYDROXY-2-OXOQUINOLINE DERIVATIVES AND OTHER COMPOUNDS AS β2 -ADRENERGIC AGONISTS |
| US20120142646A1 (en) | 2006-12-20 | 2012-06-07 | Lilian Alcaraz | Novel Compounds 621 |
| TW200833670A (en) | 2006-12-20 | 2008-08-16 | Astrazeneca Ab | Novel compounds 569 |
| GB0702456D0 (en) | 2007-02-08 | 2007-03-21 | Astrazeneca Ab | New combination |
| GB0702459D0 (en) | 2007-02-08 | 2007-03-21 | Astrazeneca Ab | Salts 669 |
| GB0702458D0 (en) | 2007-02-08 | 2007-03-21 | Astrazeneca Ab | Salts 668 |
| GB0702457D0 (en) | 2007-02-08 | 2007-03-21 | Astrazeneca Ab | New combination 666 |
| GB0703999D0 (en) | 2007-03-01 | 2007-04-11 | Astrazeneca Ab | New combination 667 |
| GB0704000D0 (en) | 2007-03-01 | 2007-04-11 | Astrazeneca Ab | Salts 670 |
| WO2009037503A2 (en) | 2007-09-18 | 2009-03-26 | Astrazeneca Ab | New combination - 012 for the treatment of respiratory diseases |
| NZ586106A (en) * | 2007-12-20 | 2012-09-28 | Astrazeneca Ab | Device, typically for medicament powder, for deaggregating powder by passing air stream along flat region with recess of brick shape where eddy is generated |
| WO2009154562A1 (en) * | 2008-06-20 | 2009-12-23 | Astrazeneca Ab | Pharmaceutical composition comprising a 4-hydroxy-2-oxo-2, 3- dihydro-1, 3-benzothiazol-7-yl compound for modulation of beta2-adrenoreceptor activity |
-
2007
- 2007-12-07 TW TW096146813A patent/TW200833670A/zh unknown
- 2007-12-19 AU AU2007336075A patent/AU2007336075B2/en not_active Ceased
- 2007-12-19 UY UY30808A patent/UY30808A1/es unknown
- 2007-12-19 MX MX2009006009A patent/MX2009006009A/es active IP Right Grant
- 2007-12-19 AT AT07848598T patent/ATE517879T1/de not_active IP Right Cessation
- 2007-12-19 EP EP07848598A patent/EP2121642B1/de active Active
- 2007-12-19 US US11/959,679 patent/US7700782B2/en not_active Expired - Fee Related
- 2007-12-19 WO PCT/GB2007/004861 patent/WO2008075026A1/en not_active Ceased
- 2007-12-19 US US12/519,552 patent/US20100022491A1/en not_active Abandoned
- 2007-12-19 JP JP2009542202A patent/JP2010513440A/ja active Pending
- 2007-12-19 KR KR1020097015062A patent/KR20090091342A/ko not_active Withdrawn
- 2007-12-19 BR BRPI0722096-0A2A patent/BRPI0722096A2/pt not_active IP Right Cessation
- 2007-12-19 CA CA002672811A patent/CA2672811A1/en not_active Abandoned
- 2007-12-20 CL CL200703765A patent/CL2007003765A1/es unknown
- 2007-12-20 AR ARP070105801A patent/AR064635A1/es not_active Application Discontinuation
- 2007-12-29 SA SA7280728A patent/SA07280728B1/ar unknown
-
2008
- 2008-01-02 PE PE2008000009A patent/PE20081544A1/es not_active Application Discontinuation
-
2009
- 2009-05-27 CO CO09054440A patent/CO6190554A2/es not_active Application Discontinuation
- 2009-05-27 IL IL199014A patent/IL199014A0/en unknown
- 2009-06-15 EC EC2009009426A patent/ECSP099426A/es unknown
- 2009-07-15 NO NO20092691A patent/NO20092691L/no not_active Application Discontinuation
-
2010
- 2010-03-30 US US12/750,014 patent/US20100249200A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA2672811A1 (en) | 2008-06-26 |
| EP2121642A1 (de) | 2009-11-25 |
| WO2008075026A1 (en) | 2008-06-26 |
| TW200833670A (en) | 2008-08-16 |
| BRPI0722096A2 (pt) | 2014-04-01 |
| ECSP099426A (es) | 2009-07-31 |
| CO6190554A2 (es) | 2010-08-19 |
| PE20081544A1 (es) | 2009-01-11 |
| AU2007336075A1 (en) | 2008-06-26 |
| US20080207698A1 (en) | 2008-08-28 |
| AU2007336075B2 (en) | 2011-10-27 |
| US20100249200A1 (en) | 2010-09-30 |
| EP2121642B1 (de) | 2011-07-27 |
| AR064635A1 (es) | 2009-04-15 |
| US7700782B2 (en) | 2010-04-20 |
| KR20090091342A (ko) | 2009-08-27 |
| NO20092691L (no) | 2009-09-16 |
| US20100022491A1 (en) | 2010-01-28 |
| UY30808A1 (es) | 2008-07-31 |
| JP2010513440A (ja) | 2010-04-30 |
| SA07280728B1 (ar) | 2010-12-01 |
| MX2009006009A (es) | 2009-06-16 |
| IL199014A0 (en) | 2010-02-17 |
| HK1136572A1 (en) | 2010-07-02 |
| CL2007003765A1 (es) | 2008-08-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0722096A2 (pt) | Compostos de 4-hidróxi-2-oxo-2,3-dihidro-1,3-benzotiazol-7-il para modulação de atividade de b2-adrenorreceptor | |
| DK2035396T3 (da) | Triazolforbindelser der modulerer hsp90-aktivitet | |
| BRPI0917634A2 (pt) | benzoxazolas, benztiazolas e análogos relacionados como moduladores de sirtuína | |
| DK2328893T3 (da) | Triazolforbindelser som modulerer hsp90 aktivitet | |
| EP2303266A4 (de) | Pharmazeutische zusammensetzung mit einer 4-hydroxy-2-oxo-2,3-dihydro-1,3-benzothiazol-7-yl-verbindung zur modulation der beta2-adrenorezeptor-aktivität | |
| DK1816935T3 (da) | System med kapsel, der har forseglingsmidler | |
| DK2952177T3 (da) | Sammensætninger, der omfatter sphingosin-1-phosphat (s1p)-receptormodulatorer | |
| LT2959894T (lt) | S1p receptoriaus moduliatoriai, skirti išsėtinės sklerozės gydymui | |
| BRPI0813304A2 (pt) | Cabeça de furadeira. | |
| BRPI0911243A2 (pt) | derivados de benzofurano, benzotiofeno, benzotiazol como moduladores de fxr | |
| DK3103448T3 (da) | Farmaceutiske sammensætninger, der omfatter en S1P-modulator | |
| BRPI0914772A2 (pt) | compostos heterocíclicos 1,2-dissubstituídos | |
| DK3031825T3 (da) | Immunbaserede aktivitetsassays for botulinum-toxin serotype a | |
| DK1863787T3 (da) | Hydrogeneret benzo[c]thiophenderivater som immunmodulatorer | |
| ATE493411T1 (de) | Pyrroloä2, 3-büpyridin-4-yl- benzolsulfonamidverbindungen als ikk2-hemmer | |
| HUE071237T2 (hu) | Fabry-kór kezelési lehetõségei | |
| DK2291368T3 (da) | Substitueret gamma-lactam som terapeutisk middel | |
| BRPI0922597A2 (pt) | "ftalazinona e análogos relacionados como moduladores de sirtuína". | |
| BRPI0818348A2 (pt) | Derivados de n-(pirazol-3-il)-benzamida como ativadores de glicocinase | |
| CR10353A (es) | Nuevos compuestos. | |
| DE602007010729D1 (de) | Tampondruckanlage | |
| DK2041128T3 (da) | Substituerede gamma-lactamer som terapeutiske agenser | |
| DK2049480T3 (da) | 2-arylindolderivater som mPGES-1-hæmmere | |
| DK2219662T3 (da) | Aktive, opløselige, post-translationelt modificerede neuregulin- isoformer. | |
| EP2098229A4 (de) | Nervenregenerationsmittel |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |